CytRx sinks on Phase III sarcoma failure

CytRx Corp. (NASDAQ:CYTR) plummeted $1.70 (68%) to $0.81 in early after-hours trading after its aldoxorubicin (formerly DOXO-EMCH, INNO-206) failed to significantly

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE